Sotatercept Reduces Pulmonary Vascular Resistance in PAH
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.